Abstract
The treatment of squamous cell carcinomas of the head and neck (HNSCC) is multidisciplinary. Chemoradiation has become an integral part of the treatment process in managing metastatic neck disease. Randomized controlled trials and meta-analyses have demonstrated major improvements not only in loco-regional tumor control, but also in terms of survival when chemotherapy is added to radiotherapy. In clinical practice, this has translated into a reduction in the number of recurrent neck disease needing salvage surgery. Studies have reported up to 2-year overall survival (OS) of 92% and disease-free survival (DFS) of 95%, in patients with advanced HNSSC treated with CRT. This single institution, retrospective cohort study was conducted to analyze the regional control rates after primary chemo-radiation therapy in a tertiary center.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
